StockData
Rhythm Pharmaceuticals, Inc. logo

Rhythm Pharmaceuticals, Inc. (RYTM) stock

RYTMNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 3, 2026Score 5/30268% above fair value
$116.61+9.13 (+8.49%)

Close on Nov 17, 2026Market cap $8.03BP/E –Yield –

Rhythm Pharmaceuticals revenue

Revenue is the money a company takes in from selling its products and services, before any costs are deducted.

Rhythm Pharmaceuticals's revenue for the twelve months ending Jun 30, 2026 was $239.92M, up 53.5% year over year. For fiscal 2025 it was $189.76M, up 45.8% from the year before. The highest annual figure on record is $189.76M in fiscal 2025.

Annual revenue

PeriodPeriod endValueChange
FY2025Dec 31, 2025$189.76M+45.8%
FY2024Dec 31, 2024$130.13M+68.1%
FY2023Dec 31, 2023$77.43M+227.6%
FY2022Dec 31, 2022$23.64M+649.5%
FY2021Dec 31, 2021$3.15M–
FY2020Dec 31, 2020$0–
FY2019Dec 31, 2019$0–
FY2018Dec 31, 2018$0–
FY2017Dec 31, 2017$0–
FY2016Dec 31, 2016$0–

Quarterly revenue

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$71.26M+46.9%
Q1 FY2026Mar 31, 2026$60.11M+83.8%
Q4 FY2025Dec 31, 2025$57.25M+36.9%
Q3 FY2025Sep 30, 2025$51.30M+54.3%
Q2 FY2025Jun 30, 2025$48.50M+66.8%
Q1 FY2025Mar 31, 2025$32.70M+25.9%
Q4 FY2024Dec 31, 2024$41.83M+72.6%
Q3 FY2024Sep 30, 2024$33.25M+47.8%
Q2 FY2024Jun 30, 2024$29.08M+51.3%
Q1 FY2024Mar 31, 2024$25.97M+126.4%
Q4 FY2023Dec 31, 2023$24.23M+175.7%
Q3 FY2023Sep 30, 2023$22.50M+425.3%
Q2 FY2023Jun 30, 2023$19.22M+112.0%
Q1 FY2023Mar 31, 2023$11.47M+665.6%
Q4 FY2022Dec 31, 2022$8.79M+383.8%
Q3 FY2022Sep 30, 2022$4.28M+316.7%
Q2 FY2022Jun 30, 2022$9.07M+3208.8%
Q1 FY2022Mar 31, 2022$1.50M+4180.0%
Q4 FY2021Dec 31, 2021$1.82M–
Q3 FY2021Sep 30, 2021$1.03M–
Q2 FY2021Jun 30, 2021$274.00K–
Q1 FY2021Mar 31, 2021$35.00K–

More Rhythm Pharmaceuticals figures

See a number that looks wrong?